Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 3, 2003 - Issue 3
Submit an article Journal homepage
19
Views
5
CrossRef citations to date
0
Altmetric
Review

Bayesian approach in pharmacoeconomics: relevance to decision-makers

Ya-Chen Tina Shih Section of Health Services Research, Unit 196, Department of Biostatistics, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 4009, USA
Pages 237-250 | Published online: 09 Jan 2014

References

  • Bayes RE An Essay Toward Solving a Problem in the Doctrine of Chances. Philos. Trans. R Son 53,370–418 (1763).
  • Barnard GA. Studies in the history of probability and statistics: IX Thomas Bayes's essay toward solving a problem in the doctrine of chances. Biomettika 45,293–315 (1958).
  • Brophy JM, Joseph L. Placing trials in context using Bayesian analysis. JAMA 273(11), 871–875 (1995).
  • •Uses the Bayesian approach to reanalyze the Global Utilization of Streptokinase and Tissue Plasminogen Activator in Occluded Arteries (GUSTO) trial. It generates a lot of interests in the Bayesian approach among health economists and outcomes researchers.
  • The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Eng/. I Med. 329,673–682 (1993).
  • Hively W The mathematics of making up your mind. Discover Magazine May, 90–97 (1996).
  • A Bayesian Approach to Economic Evaluation of Healthcare Technologies. Jones D (Ed.) . Lippincott-Raven Publishers, Philadelphia, PA, USA, 124 (1996).
  • DeGroot MR. Probability and Statistics. Addison-Wesley, Boston, MA, USA (1986).
  • Box GEP, Tiao GC. Bayesian Inference in Statistical Analysis. Wiley, New York, NY, USA (1973).
  • Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. Chapman & Hall, London, UK (1995).
  • Berry DA. Statistics: a Bayesian Perspective. Duxbury Press, Belmont, CA, USA (1996).
  • Gilks WR, Richardson S, Spiegelhalter DJ. Markov Chain Monte Carlo in Practice. Chapman & Hall, London, UK (1996).
  • Gamerman D. Markov Chain Monte Carlo: Stochastic Simulation for Bayesian Inference. Chapman & Hall, London, UK (1997).
  • Chen MH, Shao QM, Ibrahim JG. Monte Carob o Methods In Bayesian Computation. Springer-Verlag, NY, USA (2000).
  • Spiegelhalter D, Thomas A, Best N. WinBUGS Version 1.2 User Manual. MRC Biostatistics Unit. Cambridge, UK (1999).
  • Berry DA, Stangle DK. Bayesian Biostatistics. Marcel Dekker, Inc., NY, USA (1996).
  • Harrell F, E-Shih YCT. Using full probability models to compute probabilities of actual interest to decision makers. Int. J. Technol Assess. Healthcam 17(1), 17–26 (2001).
  • •Discusses the advantages of the Bayesian approach in quantifying, presenting and reporting scientific evidence. Examples were included to illustrated that probabilities computed from the Bayesian approach are more intuitively appealing to decision-makers.
  • Berger JO, Berry DA. Statistical analysis and the illusion of objectivity (430–433). Am. Scientist 76,159–165 (1988).
  • Goodman SN. Toward evidence-based medical statistics. 1: the p-value fallacy. Ann Intern. Med 130(12), 995–1004 (1999).
  • Armitage P, Berry G. Statistical Methods in Medical Research. 3rd Edition. Blackwell Scientific Publications, Oxford, UK (1994).
  • Gurrin LC, Kurinczuk JJ, Burton PR Bayesian statistics in medical research: an intuitive alternative to conventional data analysis. Eval Clin Frac 6(2), 193–204 (2000).
  • Thall PF, Sung HG. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat. In Med. 17,1563–1580 (1998).
  • Parmigiani G. Modeling- in Medical Decision Making: a Bayesian Approach. John Wiley & Sons Ltd, Chichester, UK (2002).
  • Diamond GA, Forrester JS. Clinical trials and statistical verdicts: probable grounds for appeal. Ann. Intern Med. 98,385–394 (1983).
  • Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ. 8(3), 257–261 (1999).
  • Doubilet F Begg CB, Weinstein MC et al Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med. Decis Making5, 157–177 (1985).
  • Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health 7i.chnol Assessment3(2), 1–134 (1999).
  • Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis: an illustration and application to blood pressure control in Type 2 diabetes. Int. Tchnol Assess: Healthcam17 (1), 69–82 (2001).
  • ••Gives a clear and detailed example on howto apply the Bayesian approach to compute net benefit and cost-effectiveness acceptability curve.
  • Fryback DG, Chinnis JO, Ulvila Bayesian cost-effectiveness analysis: an example using the GUSTO trial. Int. J. Ti,chnol. Assess. Healthcam 17(1), 83–97 (2001).
  • •An easy-to-follow example of a Bayesian cost-effectiveness analysis using the Windows-Based Bayesian Inference Using Gibbs Sampling Software.
  • Heitjan DF, Moskowitz AJ, Whang W Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Econ. 8, 191–201 (1999).
  • O'Hagan A, Stevens JVV, Montmartin J. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. PharmacoEcorromics17(4), 339–349 (2000).
  • ••Presents a Bayesian computation for thecost-effectiveness acceptability curve and contrasted the Bayesian approach with the frequentist approach. It explains why the interpretation of the acceptability curve is only meaningful under the Bayesian framework.
  • O'Hagan A, Stevesns JVV, Montmartin J. Bayesian cost-effectiveness analysis from clinical trial data. Stat. Med. 20,733–753 (2001).
  • O'Hagan A, Stevens RV. A framework for cost-effectiveness analysis from clinical trial data. Health Econ. 10 (4), 303–315 (2001).
  • O'Hagan A, Stevens RV. Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of healthcare technologies. Stat. Meth. Med. Res. 11, 469–490 (2002).
  • Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford University Press, Oxford, UK (1996).
  • Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Healthcam Programmes. Oxford University Press, Oxford, UK (1997).
  • Black WC. The cost-effectiveness plane: a graphic representation of cost-effectiveness. Med. Decis. Making 10(3), 212–215 (1990).
  • O'Brien BJ, Drummond ME, Labelle RJ, Willam A. In search of power and significance: issues in the design and analysis of stochastic cost effectiveness studies in healthcare. Med. Cam 32(2), 150–163 (1994).
  • Wakker P, Klaassen MR Confidence intervals for cost/effectiveness ratios. Health Econ. 4(5), 373–382 (1995).
  • Mullahy J, Manning W Statistical issues in cost-effectiveness analysis. In: Valuing Healthcare. Sloan F (Ed.). Cambridge University Press, Cambridge, UK, 149–184 (1995).
  • Fieller EC. Some problems in interval estimation.j R. Stat. Soc. Series B16,175–183 (1954).
  • Willan AR, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Econ. 5,297–305 (1996).
  • Obenchain R, Melfi C, Croghan T, Buesching D. Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy. PharmacoEconomics11, 464–472 (1997).
  • Briggs AH, Wonderling DE, Moony CZ. Pulling cost-effectiveness analysis up by its bootstraps: a nonparametric approach to confidence interval estimation. Health Econ. 6(4), 327–340 (1997).
  • Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat. Med. 15,1447–1458 (1996).
  • Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ. 6,243–252 (1997).
  • ••Provides a nice overview for the earliermethodological development for estimating the confidence interval of cost-effectiveness ratios.
  • Briggs AH, Fenn R Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 7,723–740 (1998).
  • Glick HA, Briggs AH, Polsky D. Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses. Expert Rev. Pharmacoeconomics Outcomes Res. 1(1), 25–36 (2001).
  • ••Comprehensive overview of statistical methods used to quantify uncertainty in cost-effectiveness analyses.
  • O'Brien BJ, Briggs AH. Analysis of uncertainty in healthcare cost-effectiveness studies: an introduction to statistical issues and methods. Stat. Meth. Med. Res. 11, 455–468 (2002).
  • Van Hout BA, Al MJ, Gordon GS, Rutten FFH. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 3,309–319(1994).
  • ••Landmark article that introduced theconcept of cost-effectiveness acceptability curve.
  • Stinnett AA, Mullahy J. A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med. Decis. Miking 18, S68—S80 (1998).
  • ••Introduces an innovative framework, thenet health benefit approach, for cost-effectiveness analyses. The net health benefit approach was the foundation for many Bayesian applications in pharmacoeconomics, such as the expected value of perfect information approach.
  • Tambour M, Zethraeus N, Johannesson M. A note on confidence intervals in cost-effectiveness analysis. Int. J. Tech. Assess. Healthcare 14,467–471 (1998).
  • O'Hagan A, Stevens JW. The probability of cost-effectiveness. BMC Medical Research Methodology2(5), 1–6 (2002).
  • Löthgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curve. Health Econ. 9,623–630 (2000).
  • Grieve AP. Issues for statisticians in Pharmacoeconomic evaluations. Stat. Med. 17,1715–1523 (1998).
  • Craig BA, Black MA. Incremental cost- effectiveness ratio and incremental net health benefit: two sides of the same coin. Expert Rev. Pharmacoeconomics Outcomes Res. 1(1), 37–46 (2001).
  • Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. Ltr 10,779–787 (2001).
  • Cooper NJ, Sutton AJ, Abrams KR. Decision analytical economic modeling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section. Stat. Methods Med. Res. 11,491-512 (2002).
  • Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 5, 513–524 (1996).
  • ••Proposes a research framework, known asthe value-of-information analysis, to assist decision-makers set research priorities.
  • Claxton K. Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ. 8,269–274 (1999).
  • Neumann PJ, Claxton K, Weinstein MC. The FDA's regulation of health economic information. Health Affairs 19 (5), 129–137 (2000).
  • Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet360, 711–715 (2002).
  • Raiffa H. Decision Analysis: Introductory Lectures on Chokes Under Uncertain Addisson-Wesley, WA, USA (1968).
  • Watson C, Billingsley P, Croft D, Huntsberger D. Statistics for Management and Economics. Allyn and Bacon, Needham Heights, MA, USA (1990).
  • Spurr W, Bonini C. Decision_ making- and sampling: the normal distribution. Statistical analysis for business decisions. Richard D. Irwin Inc., Homewood, IL, USA (1973).
  • Claxton K. The irrelevance of inference: a decision making approach to the stochastic evaluation of healthcare technologies. Health. Econ. 18,341–364 (1999).
  • Claxton K, Neumann PJ, Araki S, Weinstein MC. Bayesian value-of-information analysis. Int. j Technol. Assess. Healthcare 17(1), 38–55 (2001).
  • •Straightforward example was presented in this article to demonstrate how to use the value-of-information analysis to assist allocation decisions.
  • Claxton K, Thompson KM. A dynamic programming approach to the efficient design of clinical trials. J. Health Econ. 20, 797–822 (2001).
  • Spiegelhalter DJ, Myles JP, Jones DT, Abrams KR. Bayesian methods in health technology assessment: a review. Health Technol. Assess. 4(38), (2000).
  • Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. An introduction to Bayesian methods in health technology assessment. Brit. Med 319,508–512 (1999).
  • Heitjan DE Bayesian interim analysis of Phase 2 cancer clinical trials. Stat. Med. 16, 1791–1802 (1997).
  • Stevens JW, O'Hagan A. Incorporation of genuine prior information in cost-effectiveness analysis of clinical trial data. kit.j Tech. Assess. Healthcare 18(4), 782–790 (2002).
  • Carlin BP, Louis TA. Bayes and Empirical Bayes Methods For Data Analysis. Chapman and Hall, London, UK (1996).
  • Raftery A, Richardson S. Model selection for generalized linear models via GLIB: application to nutrition and breast cancer. Berry D, Stangl D (Eds). In: Bayesian Biostatistics. Marcel Dekker, Inc., NY, USA, (1996).
  • O'Hagan A. Bayesian Inference. Kendall's Advanced Theory of Statistics, Volume 2B. 1st Edition, John Wiley & Sons Inc., NY, USA (1994).
  • Luce BR, Claxton K. Redefing the analytical approach to pharmacoeconomics. Health Econ. 8(3), 187–189 (1999).
  • Luce BR, Shih YCT, Claxton K. Bayesian approaches to technology assessment and decision making. Int. J. Technol. Assess. Healthcare 17(1), 105 (2001).
  • Thompson S. Statistical issues in cost- effectiveness analyses. Stat. Med. 11, 453–454 (2002).
  • Fryback DG, Stout NK, Rosenberg MA. An elementary introduction to Bayesian computing using WinBUGS. Int. J. Technol. Assess. Healthcare 17(1), 98–113 (2001).
  • ••Provides a user-friendly tutorial of theWindows-based Bayesian Inference Using Gibbs Sampling Software using two easy-to-follow examples.

Websites

  • www.nice.org.uk (Accessed May 2003). National Institute for Clinical Excellence. Technical guidance for manufacturers and sponsors (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.